UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 477

Sortiert nach

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Alzheimer's research & therapy, 2021-04, Vol.13 (1), p.80-14, Article 80

2021

Volltextzugriff (PDF)

The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans

Pain (Amsterdam), 2007-11, Vol.132 (1), p.132-141

2007

Volltextzugriff (PDF)

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Alzheimer's research & therapy, 2022-05, Vol.14 (1), p.70-70, Article 70

2022

Volltextzugriff (PDF)

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease

Biomolecules (Basel, Switzerland), 2016-04, Vol.6 (2), p.19-19

2016

Volltextzugriff (PDF)

Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury

European journal of pain, 2011-11, Vol.15 (10), p.1040-1048

2011

Volltextzugriff (PDF)

A Randomized, Placebo-controlled Trial of the Analgesic Efficacy and Safety of the p38 MAP Kinase Inhibitor, Losmapimod, in Patients With Neuropathic Pain From Lumbosacral Radiculopathy

The Clinical journal of pain, 2015-04, Vol.31 (4), p.283-293

2015

Volltextzugriff (PDF)

Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding

Brain (London, England : 1878), 2006-08, Vol.129 (8), p.2017-2028

2006

Volltextzugriff (PDF)

Erratum: Lai, R.Y.K.; Harrington, C.R.; Wischik, C.M. Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease. Biomolecules 2016, 6, 19

Biomolecules (Basel, Switzerland), 2016-08, Vol.6 (3), p.35

2016

Volltextzugriff (PDF)

A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease

Journal of Alzheimer's disease, 2010-01, Vol.22 (4), p.1241

2010

Volltextzugriff (PDF)

Voxel-Based Analysis of 11C-PIB Scans for Diagnosing Alzheimer's Disease

The Journal of nuclear medicine (1978), 2008-08, Vol.49 (8), p.1262-1269

2008

Volltextzugriff (PDF)

A Comparison of Gray Matter Density in Restless Legs Syndrome Patients and Matched Controls Using Voxel-Based Morphometry

Journal of neuroimaging, 2012-01, Vol.22 (1), p.28-32

2012

Volltextzugriff (PDF)

Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease

Journal of Alzheimer's disease, 2008-07, Vol.14 (3), p.301

2008

Volltextzugriff (PDF)

P2-444: A novel potent histamine H3 receptor antagonist produces discrete changes in brain activity during learning and episodic memory: Implications for cognitive enhancement

Alzheimer's & dementia, 2008-07, Vol.4 (4), p.T503-T504

2008

Volltextzugriff (PDF)

P4-373: Predictors of placebo group decline in the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) in 24-week clinical trials of Alzheimer's disease

Alzheimer's & dementia, 2008-07, Vol.4 (4), p.T783-T783

2008

Volltextzugriff (PDF)

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A[beta] protofibril antibody

Alzheimer's research & therapy, 2022-05, Vol.14 (1)

2022

Volltextzugriff (PDF)

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A[beta] protofibril antibody

Alzheimer's research & therapy, 2021-04, Vol.13 (1)

2021

Volltextzugriff (PDF)

P1‐055: E2027, A NOVEL PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_5), p.P289-P289

2018

Volltextzugriff (PDF)

E2027, A NOVEL PHOSPHODIESTERASE-9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P289-P289

2018

Volltextzugriff (PDF)

P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_30)

2019

Volltextzugriff (PDF)

P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

Alzheimer's & dementia, 2019-07, Vol.15, p.P1582-P1583

2019

Volltextzugriff (PDF)

POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P1582-P1583

2019

Volltextzugriff (PDF)

BAN2401 IN EARLY ALZHEIMER'S DISEASE: NEURODEGENERATION BIOMARKER ANALYSIS FROM A RANDOMIZED PHASE 2 STUDY

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P1484-P1484

2019

Volltextzugriff (PDF)

DT‐01‐01: BAN2401 IN EARLY ALZHEIMER'S DISEASE: NEURODEGENERATION BIOMARKER ANALYSIS FROM A RANDOMIZED PHASE 2 STUDY

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_28), p.P1484-P1484

2019

Volltextzugriff (PDF)

O1‐12‐06: PHASE 1 MULTIPLE ASCENDING DOSE (MAD) STUDY OF PHOSPHODIESTERASE‐9 INHIBITOR E2027: CONFIRMATION OF TARGET ENGAGEMENT AND SELECTION OF PHASE 2 DOSE IN DEMENTIA WITH LEWY BODIES

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_4), p.P251-P251

2018

Volltextzugriff (PDF)

DT‐01‐07: TREATMENT OF EARLY AD SUBJECTS WITH BAN2401, AN ANTI‐Aβ PROTOFIBRIL MONOCLONAL ANTIBODY, SIGNIFICANTLY CLEARS AMYLOID PLAQUE AND REDUCES CLINICAL DECLINE

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_31), p.P1668-P1668

2018

Volltextzugriff (PDF)

1 – 25 von 477

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(444)
Mit Volltextzugriff
(417)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(353)
Life Sciences & Biomedicine
(267)
Humans
(222)
Female
(125)
Male
(125)
Biological And Medical Sciences
(89)
Middle Aged
(87)
Adult
(69)
Medical Sciences
(69)
Animals
(67)
Aged
(62)
Physical Sciences
(44)
Technology
(43)
Biochemistry & Molecular Biology
(38)
Neurosciences & Neurology
(33)
Adolescent
(31)
Fundamental And Applied Biological Sciences. Psychology
(28)
Science & Technology - Other Topics
(28)
Aged, 80 And Over
(26)
Ophthalmology
(26)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease

Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury

A Randomized, Placebo-controlled Trial of the Analgesic Efficacy and Safety of the p38 MAP Kinase Inhibitor, Losmapimod, in Patients With Neuropathic Pain From Lumbosacral Radiculopathy

Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding

Erratum: Lai, R.Y.K.; Harrington, C.R.; Wischik, C.M. Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease. Biomolecules 2016, 6, 19

A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease

Voxel-Based Analysis of 11C-PIB Scans for Diagnosing Alzheimer's Disease

A Comparison of Gray Matter Density in Restless Legs Syndrome Patients and Matched Controls Using Voxel-Based Morphometry

Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease

P2-444: A novel potent histamine H3 receptor antagonist produces discrete changes in brain activity during learning and episodic memory: Implications for cognitive enhancement

P4-373: Predictors of placebo group decline in the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) in 24-week clinical trials of Alzheimer's disease

Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A[beta] protofibril antibody

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A[beta] protofibril antibody

P1‐055: E2027, A NOVEL PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

E2027, A NOVEL PHOSPHODIESTERASE-9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM

P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES

BAN2401 IN EARLY ALZHEIMER'S DISEASE: NEURODEGENERATION BIOMARKER ANALYSIS FROM A RANDOMIZED PHASE 2 STUDY

DT‐01‐01: BAN2401 IN EARLY ALZHEIMER'S DISEASE: NEURODEGENERATION BIOMARKER ANALYSIS FROM A RANDOMIZED PHASE 2 STUDY

O1‐12‐06: PHASE 1 MULTIPLE ASCENDING DOSE (MAD) STUDY OF PHOSPHODIESTERASE‐9 INHIBITOR E2027: CONFIRMATION OF TARGET ENGAGEMENT AND SELECTION OF PHASE 2 DOSE IN DEMENTIA WITH LEWY BODIES

DT‐01‐07: TREATMENT OF EARLY AD SUBJECTS WITH BAN2401, AN ANTI‐Aβ PROTOFIBRIL MONOCLONAL ANTIBODY, SIGNIFICANTLY CLEARS AMYLOID PLAQUE AND REDUCES CLINICAL DECLINE

Suchergebnisse filtern